Lot numbers appear on both individual vials and the box, and begin with alpha numeric codes such as L1, K1 or H1. 

1

The packaging and/or vials.

Proof of purchase between March 2014 and October 2015.

2

Any documented evidence of your out-of-pocket expenses, such as receipts or bank statements that may highlight the drug.

Any documents concerning your treatments / procedures.

3

Any documents concerning your fertility treatments and medical procedures for which was prescribed, including all documents evidencing your out-of-pocket expenses. 

About The Allergan Biocell Textured Breast Implants Case:

This lawsuit comes in the wake of the FDA's request that Allergan issue a recall of its Biocell textured breast implants and tissue expanders. Allergan agreed and is removing these products from the global market. The FDA requested the recall based on newly submitted Medical Device Reports reporting worldwide cases of BIA-ALCL and BIA-ALCL-related deaths associated with these implants.

*Required Fields

This is attorney advertising. Past results cannot be an assurance of future success in any given case, because each matter must be decided on its own merits.



Click Here to Read the Class Action Complaint

To speak with us on a confidential basis about your Allergan Biocell implants, or to learn how you can join the class action, please complete the contact form below. Your consultation with our law firm will be free of charge.

The typical things needed to move forward:

aabramowitz@bm.net

(215) 875-3015 

bergermontague.com

Berger Montague
1818 Market Street, Suite 3600
Philadelphia, PA 19103

Andrew Abramowitz, Esq. 

Counsel Information:

Copyright 2021 Berger Montague
1818 Market Street, Suite 3600, 

Philadelphia, PA 19103
(800) 424-6690
|
info@bm.net

Berger Montague Investigates Securities Fraud Allegations Against Unity Software Inc. (NYSE: U); Lead Plaintiff Deadline is September 6, 2022.

Join the class action against Unity Software Inc.: 

Berger Montague has filed a nationwide class action lawsuit against medical device manufacturer Allergan to protect women from the harmful Biocell Textured Breast Implant. The case is Alabama Doe, et al. v. Allergan, Inc., et al.

On July 24, 2019, Allergan announced a recall of certain Biocell textured breast implants after reports showed a possible link between the implants and a type of non-Hodgkin's lymphoma (cancer of the immune system).

Our class action claims the recall doesn't fully compensate proposed class members for the costs of replacing or retaining their implants and aims to force Allergan to pay for the costs of surgery, diagnostic testing, and medical monitoring in people who have Biocell implants.

Double-click to edit this text

Michael Dell’Angelo, Esq.

mdellangelo@bm.net

(215) 875-3080

bergermontague.com

Berger Montague
1818 Market Street, Suite 3600
Philadelphia, PA 19103

About the Unity Software Inc. Class Action: 

On May 10, 2022, after the market closed, Unity announced its first quarter 2022 financial results. The Company reduced its fiscal 2022 guidance due to challenges with monetization products. Specifically, “a fault in [the Company’s] platform . . . resulted in reduced accuracy for [its] Audience Pinpointer tool, a revenue expensive issue given that [the] Pinpointer tool experienced significant growth post the IDFA changes.”

On this news, Unity’s stock fell $17.83 per share – 37% – to close at $30.30 per share on May 11, 2022.

The complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that: (1) deficiencies in Unity’s product platform reduced the accuracy of the Company’s machine learning technology; (2) the foregoing was likely to have a material negative impact on the Company’s revenues; and (3) accordingly, Unity had overstated its commercial and financial prospects for 2022.